We report a patient with severe hypertriglyceridemia associated with anemia and hypoalbuminemia, in which the former may have caused the latter two conditions. This is the first reported case of abrupt onset of severe hypertriglyceridemia resulting in suppression of bone marrow and liver function. J Atheroscler Thromb, 2003; 10: 192-201.
Introduction
Chylomicrons and very-low-density lipoproteins (VLDLs) are primarily involved in exogenous and endogenous triglyceride transport, respectively. Cellular uptake of triglyceride from chylomicrons and VLDLs occurs at the endothelial surface and requires the action of lipoprotein lipase (LPL) as well as its cofactor, apoprotein C-II (apoC-II). Therefore, primary hypertriglyceridemia has been described as LPL deficiency, and secondary hypertriglyceridemia has been associated with diabetes mellitus, nephrotic syndrome, hypothyroidism, obesity, and hyperadrenocorticism. It is also known that hypertriglyceridemia may be associated with other diseases. Recently, a relationship between serum triglyceride level and fatty liver has been reported (1) . We report here a case of severe hypertriglyceridemia associated with anemia and hypoalbuminemia, in which the former may have caused the latter two conditions.
Methods and Materials

Assay methods
The serum concentrations of total cholesterol (TC) and triglyceride (TG) were determined by an enzymatic method, while high-density lipoprotein cholesterol (HDL-C) was determined by the precipitation method. Hemoglobin A1c was measured by high-performance liquid chromatography. The other biochemical analyses and blood cell analyses were determined in a central clinical laboratory using an autoanalyzer.
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and agarose gel electrophoresis
The lipoproteins prestained by Sudan Black B were fractionated electrophoretically in a 3% polyacrylamide disc gel. Electrophoresis was allowed to proceed at 3 mA per gel tube for 50 min, by which time the HDL-C band reached about 5 mm above the bottom of the tubes.
Agarose gel electrophoresis was carried out using a commercial kit (Rep Lipo-30 plate, KK Helena Kenkyujo, Saitama, Japan). An agarose solution (0.05 mol/l barbital buffer, pH 8.6) was poured onto a 0.38-mm sheet of polyester film on a horizontal table and evenly spread over the film. One microliter of serum was placed in each slit and the electrophoresis was carried out for 40 min at 90 V. After electrophoresis, the plate was dried at 60ºC and stained for 30 min in Fat Red 7B.
Preparation of lipoproteins
The patient's blood samples were collected into tubes containing EDTA (ethylenediaminetetraacetic acid, 0.1% final concentration). After separation of the plasma, the lipoproteins were isolated by stepwise-density sequential ultracentrifugation.
Determination of LPL and hepatic triglyceride lipase (HTGL) activities in postheparin plasma (PHP)
Postheparin blood was collected into a tube containing EDTA-2Na 10 min after an intravenous injection of 30 U/kg body weight of heparin (Novo Nordisk, Bagsvaerd, Denmark), after which PHP was immediately separated by lowspeed centrifugation (1,700 × g) at 4ºC for 10 min and stored at -70ºC until analysis. Activities of LPL and lipoprotein triglyceride lipoprotein lipase (HTGL) in PHP were measured with an emulsion of triolein as a substrate. HTGL activity was determined following inhibition of LPL activity by protamine sulfate. Both lipase activities are expressed as free fatty acid (FFA) formed per minute, and enzyme activity is defined as micromoles FFA per milliliter PHP per minute.
Determination of LPL mass in PHP
The LPL mass in PHP was also determined by enzymelinked immunosorbent assay using a Markit F LPL kit (Dainippon Pharmaceutical, Tokyo, Japan).
Quantification of apoB-48 and apoB-100
Apoprotein B-48 (apoB-48) and apoprotein apoB-100 (apoB-100) were isolated from plasma in the lipoprotein fraction with a density less than 1.006 g/ml using ultracentrifugation (627,000 × g; TLA-20 ultracentrifuge, Beckman, Fullerton, USA). Lipoproteins, which were separated from other lipoproteins, was defatted, dried, and subjected to SDS-PAGE. After electrophoresis, separated apoB-48 and apoB-100 were electrophoretically transferred to nitrocellulose membranes (Millipore, Tokyo, Japan) using semidry blotting. ApoB-48 and apoB-100 bands were identified and visualized using an antibody against apoB obtained from Daiichi Pure Chemicals (Tokyo, Japan) and subsequently an antirabbit immunoglobulinG (lgG) antibody (horseradish peroxidase (HRP) conjugated; Amersham Pharmacia Biotech, Buckinghamshire, UK) using enhanced chemiluminescence (ECL™; Amersham Pharmacia Biotech, Buckinghamshire, UK).
Western blotting for PPARα, PPARδ, PPARγ, and low-density lipoprotein (LDL) receptor of liver biopsy specimen The patient's liver biopsy specimens were obtained on Aug 14, 2000. He was treated with atorvastatin (HMGCoA reductase inhibitor) at 40 mg/day, bezafibrate (fibrate) at 400 mg/day, cholestimide (anion-exchange resin) at 3 g/day, and eicosapentaenoic acid (EPA) at 1.8 g/day. We used the nuclear extract of the liver biopsy specimens for analysis of PPARα, PPARδ and PPARγ. Moreover, we used the total cell extract of the liver biopsy specimens for analysis of LDL receptor. Western blotting for PPARα, PPARδ, PPARγ and LDL receptor of liver biopsy specimens was performed with a specific antibody using an Amersham ECL kit. Briefly, total cell or nuclear extract of the liver biopsy specimen, which were applied as the same protein mass, was subjected to 10% SDS-PAGE and transferred to nitrocellulose membranes (Millipore) by semidry blotting. The membranes were treated overnight with TBS-Tween/5% dry milk and incubated with goat antihuman PPARα, PPARδ and PPARγ antibodies for 1 hour. Antibodies against human PPARα, PPARδ and PPARγ were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA), and the antibody against LDL receptor was obtained from Oncogene Science. After washing, membranes were incubated with HRP-conjugated rabbit antigoat lgG antibody. Antigen detection was performed with a chemiluminescence detection system.
LDL receptor activity assay by fluorescenceactivated cell-sorter flow cytometry
The binding and uptake of a fluorescently labeled LDL (Dil-LDL, Molecular Probes) by the LDL receptor was measured in peripheral lymphocytes, whose receptors had been upregulated in primary culture. The fluorescence-activated cell sorting was done by a flow cytometer according to the methods reported by Ranganathan et al. (2) . All results are expressed as mean intensity of fluorescence (MIF) after subtracting the background values (MIF typically less than 50) obtained in the presence of 2 mM ethyleneglycoltetraacetic acid. LDL receptor activities were represented as a percentage of the average MIF in healthy controls. The intra-and inter-assay coefficients of variation were less than 10% and 15%, respectively.
Case Report
The patient, a 22-year-old male student, was admitted to our hospital because of palpitation and headache on Aug 2, 2000 (Table 1 ). His body weight and height were 52.6 kg and 174.7 cm, respectively, giving a body mass index of 17.2. He had been aware of mild back pain several times a year during the previous 4 years. Four months before admission, a regular health checkup at his university had revealed glycosuria. Based on a diagnosis of type-2 diabetes mellitus and chronic pancreatitis, treatment with insulin injection (Fig. 1 ) and a trypsin inhibitor, camostat mesilate, was started, which resulted in a gradual decrease in the patient's plasma glucose levels. There were no signs of hyperlipidemia, anemia, or liver dysfunction at this time ( Fig. 1 , Table 1 ). Three months before admission, the levels of serum TG and TC were 202 and 215 mg/dl, respectively ( Table 1) . The patient did not drink alcohol and there was no family history of hyperlipidemia. Physical examination on admission revealed no xanthomas. However, the optic fundi demonstrated retinal lipemia (Fig. 2) . Laboratory examinations revealed serum TG and TC levels of 8,800 mg/dl and 3,820 mg/dl, respectively (Table 1) . A serum sample was opalescent after being left to stand overnight at 4ºC, and no chylomicrons were evident (Fig. 3) . SDS-PAGE and agarose gel electrophoresis revealed type-V hyperlipoproteinemia (Fig. 4A) , without a broad-β band (Fig. 4B) . Secondary hyperlipidemia, such as that seen in cases of nephrotic syndrome (urine protein was negative; creatinine clearance 137 ml/min), and hypothyroidism (free triiodothyronine 3.42 pg/ml, free thyroxine 0.82 ng/ml, thyroid-stimulating hormone 0.592 µIU/ml), was ruled out. Protein electrophoresis showed a normal pattern (Fig. 5) , and his serum IgG, IgM, and IgA levels were normal (data not shown). More detailed laboratory examination (Table 2) of the lipoproteins revealed that the mass of LPL, postheparin lipolytic activity, and activity of HTGL were 237 ng/ml (normal range 136-321 ng/ml), 0.382 mmol FFA/ml/min, and 0.21 mmol FFA/ml/min, respectively. His apoE phenotype was 3/3 wild type. The LDL recep- tor activity in stimulated human T-lymphocytes was characterized by flow cytometry. His LDL receptor activity was 73% (normal > 80%). Western blot analysis indicated that LDL receptor protein levels were markedly upregulated in his liver biopsy specimen as compared with those in a normal control liver obtained from a healthy man (Fig. 6) . The gel chromatography (Sephadex S-300) for his ultracentrifugally separated VLDLs ( < 1.006 g/ml fraction) showed that the range of lipoprotein sizes was almost the same as that of normal VLDLs (Fig. 7) . The patient's dietary fat intake was restricted to 10 g/day, resulting in a decreased level of apoB-48 derived from exogenous lipoprotein (Fig. 8) , while the level of apoB-100, derived from endogenous lipoprotein, was not altered (Fig. 8) .
To improve the hyperlipidemia further, we administered atorvastatin at 40 mg/day, bezafibrate at 400 mg/day, cholestimide at 3 g/day, and EPA at 1.8 g/day (3). This intensive treatment transiently lowered the serum TG and TC levels to 3,820 mg/dl and 765 mg/dl, respectively. He received the insulin therapy Penfil 30R at 10 U/day in the morning, resulting in a fasting plasma glucose level of 99 mg/dl. However, after 1 week the TG levels increased again to over 4,000 mg/dl in spite of strict control of glucose intake (the time courses of the concentrations of serum lipids are shown in Fig. 1 ). Therefore, we performed LDL apheresis once a week (LA-15, Kanegafuchi, Osaka, Japan) to prevent atherosclerosis and pancreatitis. It has been reported that LDL apheresis can remove particles containing apoB-100, such as VLDLs and intermediate lipoprotein, in addition to LDL particles (4). The LDL apheresis once a week for 19 months was effective in reducing the levels of TG and TC to 542 mg/dl and 199 mg/dl, respectively (Fig. 1) . The patient's hemoglobin level was 11.9 g/dl, and the serum total protein and albumin levels were 10.1 g/dl and 3.1 g/dl, respectively. His serum was creamy pink in color, similar to a strong strawberry milkshake. Laboratory tests can be misleading in the presence of marked hypertriglyceridemia; chylomicrons may directly affect the determination of hemoglobin and serum albumin levels. Thus, it is possible that the patient's blood levels of hemoblobin and albumin may have been falsely increased. However, when we determined these levels after centrifugation, the extent of anemia and hypoalbuminemia become more obvious. Along with a marked decrease in the TG level after LDL apheresis, severe normocytic normochromic anemia (hemoglobin level 8.3 g/ dl; hematocrit 23.8%) and severe hypoalbuminemia (2.6 g/dl) were observed. Bone marrow aspiration (Fig. 9A ) revealed a decreased number of erythroblasts (Table 3) , but interestingly foam cells (Fig. 9B, arrow) , possibly derived from macrophages, were present. Despite the severe anemia, no serum erythropoietin was detectable (Table 4) . A liver biopsy specimen revealed fat-laden hepatocytes (hepatic steatosis) (Fig. 10A, B) with basophilic bodies (arrowhead) (Fig. 9B) , which appeared Not change as compared with control Fig. 11 . Liver biopsy specimens (electron microscopy): 1,500 × 1.7 (A), 5,000 × 1.7 (B), and 3,000 × 1.7 (C).
whorl-shaped ( Fig. 11A, B ; arrow) by electron microscopy. Moreover, we observed branching anastomosing coarsethread-like structures known as nucleolonema ( Fig.  11C; arrowhead) . Multiple mitochondria were mobilized at the surface of the lipid (Fig. 11A) . Western blot analysis indicated that levels of PPARα, PPARδ, and PPARγ proteins were markedly increased in the nuclear extract of his liver biopsy specimen as compared with those in a normal control liver obtained from a healthy man (Fig.  12) . As of November 1, 2002, our patient had not received LDL apheresis for 7 months (from April 20, 2002), and his TG and TC levels were 194 mg/dl and 131 mg/dl, respectively. In addition, his hemoglobin and serum albumin levels were 9.7 g/dl and 4.2 g/dl, respectively, and his serum erythropoietin level was normalized (9.7 mIU/ml) by treatment with hypolipidemic drugs (Fig. 1, Fig. 13 ).
Discussion
Okamoto et al. reported a patient with hypertriglyceridemia, which was associated with chylomicrons that might have been caused by reduction of LPL and HTGL, and with anemia (5). Moreover, Osono et al. reported the relationship between serum triglyceride levels and fatty liver (1), but did not clarify how hypertriglyceridemia was associated with anemia or fatty liver. Therefore, we attempted to clarify the relationship of hypertriglceridemia with anemia and/or fatty liver (hypoalbuminemia) by obtaining a detailed lipid profile, bone marrow aspiration, and liver biopsy in a patient with transient severe hypertriglyceridemia.
First of all, secondary hypertriglyceridemia, such as seen in cases of nephrotic syndrome, hypothyroidism, and diabetes mellitus, was ruled out. The presence of significant chylomicrons in the patient's plasma would have resulted in a creamy layer at the top of the plasma sample; however his serum sample was opalescent after being left to stand overnight at 4ºC, and there was no such creamy layer (Fig. 3) . The patient's abnormal lipoprotein appeared to have been caused by the overproduction of VLDLs by the liver rather than overaccumulation of blood chylomicrons, as based on the detailed lipid analysis using SDS-PAGE (Fig. 4) , agarose gel electrophoresis (Fig. 4) , gel chromatography (Fig. 7) , ultracentrifugation (Table 2), LPL (Table 2) , and Western blotting for apoB (Fig. 8) . Although the detailed mechanisms of oversecretion of VLDLs from the liver are not clear, recent attention has been focused on a lipid regulator, microsomal TG transfer protein (MTP), which may be a promising therapeutic target. In fact, MTP inhibitors can decrease VLDLs overproduction by the liver. Although phase-I trials of MTP inhibitors are currently underway in Germany (6), these inhibitors are not yet commercially available. Moreover, the whorl-like structures (Fig. 11A,   Fig. 12 . Western blot analysis of PPARα, PPARδ, and PPARγ proteins in normal control liver (A) and the patient's liver (B). B; arrow) in our patient's liver biopsy specimen as observed by electron microscopy are of interest, being similar to the surfactant-like particles (7, 8) in phosphatidylcholine-rich membranes produced in the small intestine. Their secretion is increased by fat intake, although this is the first reported association of the surfactant-like particles with secretion of VLDLs by the liver.
In spite of severe hypertriglyceridemia, our patient's LPL protein mass did not indicate upregulation of LPL (Table  2) . Abnormal regulation of transcription of LPL may have been present. Our data from Western blotting indicated that the hepatic PPARs protein levels were markedly increased by treatment of PPARs agonists (Fig. 12) . Bezafibrate was PPARα and PPARδ agonist, while EPA was PPARα and PPARγ agonist. Despite the upregulation of the PPARs by PPARs agonists in our patient's liver, why were the protein mass of his LPL also not upregulated? This may reflect an abnormality in transcriptional coactivators for PPARs, such as cAMP response elementbinding protein (CREB)-binding protein (CBP)/p300. The disturbance of regulation of transcription of target genes by PPARs in liver might have affected the process of steatosis, resulting in decreased production of albumin by the liver. We treated this patient with a combination of statin and fibrate, which may produce side effects of rhabdomyolysis or myopathy; however, such side effects were not observed. Moreover, in addition to fibrate and statin we continued to treat the patient with EPA (1.8 g/day), nicotinic tocopherol (600 µg/day), and aspirin (81 mg/ day).
Secondly, we investigated the relationship between hypertriglyceridemia and anemia. Our patient's anemia was normochromic and normocytic, and so gastrointestinal bleeding was not likely. Interestingly, his bone marrow aspirate indicated reduction of megakaryocytes, myeloid cells, and erythroid cells. In 1987, Irani et al. reported that transient hypertriglyceridemia was associated with pure red-cell anemia (9) . However, the present case differed from pure red-cell anemia, which is a congenital disorder characterized by failure of erythropoiesis, with a low reticulocyte count and a high erythropoietin level. In our patient, erythropoietin was not detectable in spite of severe anemia, and the number of reticulocytes was normal. Moreover, his serum-soluble transferrin receptor level was low, which was compatible with his markedly reduced erythropoietin level, and as shown in Fig. 13 , the reduction of serum triglyceride levels was associated with the improvement of anemia. In addition, his erythropoietin level gradually increased (Table  4) to normal (Fig. 1) . Although the detailed mechanisms remain to be clarified, the improved metabolism of VLDLs, chylomicrons, or their remnants might ameliorate the regulation of erythropoietin. If our hypothesis is correct, it is very important to control not only plasma glucose but also plasma lipid metabolism in diabetes mellitus, in order to prevent renal anemia. One more point to be noted is that the lymphocyte percentage in our patient reached 63% (normally 28-44%). As shown in Table 5 , all the virus titers we determined were negative. It has been reported that pure red-cell aplasia might be associated with parvovirus B19 infection (10) , and that autoimmune hemolytic anemia may also occur in the course of infection by the Epstein-Barr virus (11) . We cannot exclude the possibility that our patient's transient hypertriglyceridemia was caused by other viruses.
To our knowledge, this is the first reported case of abrupt onset of severe hypertriglyceridemia, resulting in suppression of bone marrow and liver dysfunction. The exact mechanisms responsible for the severe hypertriglyceridemia in relation to anemia and hypoalbuminemia remain to be clarified. 
